California Supreme Court to Hear Gilead Drug Liability Case
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy GILD?
Source: Newsfilter
- Legal Responsibility Review: The California Supreme Court is set to hear Gilead's appeal regarding whether drug manufacturers are obligated to continue developing allegedly safer alternatives, a decision that could reshape product liability law and impact innovation in the pharmaceutical industry.
- Patient Lawsuit Background: Approximately 24,000 HIV patients have sued Gilead, alleging that the company halted the development of TAF, a drug with fewer side effects, to protect the market for TDF, potentially increasing health risks for patients.
- Debate on Innovation and Liability: In its appeal, Gilead argues that allowing patients to sue would stifle innovation, as drugmakers could face liability for failing to commercialize new drugs, which may ultimately reduce the development of new treatments.
- Profit vs. Ethical Considerations: Patients contend that Gilead made billions in additional profits from TDF after its patent expired in 2017, questioning the reasonableness of the decision to delay TAF's commercialization and highlighting the ethical responsibilities of pharmaceutical companies in balancing profit and patient health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 134.060
Low
105.00
Averages
137.88
High
154.00
Current: 134.060
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Akamai Technologies Shares Surge 27% on $1.8 Billion Commitment
- Akamai Stock Surge: Shares of Akamai Technologies soared 27% after a leading U.S. frontier model provider committed to a $1.8 billion investment over seven years for its Cloud Infrastructure Services, enhancing market confidence and potentially driving future revenue growth.
- CoreWeave Revenue Guidance Miss: CoreWeave's second-quarter revenue guidance of $2.45 billion to $2.6 billion, with a midpoint of $2.53 billion, fell short of Wall Street's $2.69 billion expectation, resulting in a 7% stock decline, reflecting market concerns about its growth outlook.
- Microchip Earnings Beat: Microchip Technology's stock rose 3% following a fiscal fourth-quarter report that exceeded earnings and revenue expectations, with projected first-quarter revenue between $1.44 billion and nearly $1.47 billion, indicating strong performance in the semiconductor sector.
- Upwork Restructuring Plan: Upwork's announcement of a 24% workforce reduction to maintain profitability led to a 23% drop in its stock price, despite slightly lower-than-expected first-quarter earnings and revenue, showcasing the company's strategic response to evolving market conditions.
See More
Gilead Sciences Q1 2026 Earnings Call Highlights
- Significant Sales Growth: Gilead Sciences reported total product sales of $6.8 billion in Q1, an 8% year-over-year increase, with HIV sales reaching $5 billion, reflecting a robust 10% growth that underscores its strong market position and share gains in the HIV sector.
- Yeztugo Guidance Raised: Management has increased the 2026 Yeztugo sales guidance to approximately $1 billion, indicating confidence in product acceptance, while also projecting an 8% year-over-year growth in HIV sales, surpassing the previous guidance of 6%.
- Strong Financial Performance: The company reported a non-GAAP diluted EPS of $2.03, beating expectations by $0.12, with a product gross margin of 87% and an operating margin of 47%, showcasing its strengths in cost control and profitability.
- Positive Future Outlook: Management highlighted upcoming regulatory catalysts, including the priority review of BIC/LEN, which is expected to drive future revenue growth, while also noting a potential 2% growth headwind from policy changes that requires cautious navigation.
See More
Gilead Sciences Updates 2026 EPS Guidance to Loss Amid Q1 Beat
- EPS Guidance Cut: Gilead Sciences has drastically revised its 2026 non-GAAP EPS guidance from a profit of $8.45-$8.85 to a loss of $1.05-$1.65, primarily due to $11.5 billion in IPR&D charges and financing costs, which has negatively impacted market confidence.
- Sales Forecast Increased: Despite the EPS downgrade, Gilead projects full-year product sales of $30 billion to $30.4 billion, up from a prior estimate of $29.6 billion to $30 billion, indicating ongoing growth potential in its HIV and oncology treatment sectors.
- Significant HIV Growth: In Q1, Gilead's HIV franchise saw approximately a 10% year-over-year sales increase to around $5 billion, with Biktarvy alone generating about $3.4 billion, further solidifying its leadership in the antiviral market.
- Cash Flow Decline: As of March 31, 2026, Gilead's cash, cash equivalents, and marketable securities totaled $8.6 billion, down from $10.6 billion on December 31, 2025, reflecting financial pressure from acquisitions and R&D investments.
See More
Gilead Raises 2026 Sales Guidance Amid Acquisition Strategy
- Sales Guidance Increase: Gilead raised its 2026 product sales guidance to $30.0–$30.4 billion from $29.6–$30.0 billion, reflecting confidence in future growth despite pressures from acquisition-related costs.
- Aggressive Acquisition Strategy: The company is actively pursuing acquisitions, having announced deals for Arcellx, Ouro Medicines, and Tubulis since the start of 2026, aiming to bolster its oncology and inflammation pipeline while maintaining resilience in its HIV franchise.
- Strong Earnings Report: Gilead reported first-quarter revenues of $7.0 billion, a 4% year-over-year increase, with product sales rising 5% to $6.9 billion and HIV product sales growing 10% to $5.0 billion, demonstrating the strength of its core business.
- Earnings Outlook Cut: Despite the sales guidance increase, Gilead slashed its 2026 adjusted loss guidance to a range of $1.05 to $0.65 per share, down from previous earnings estimates of $8.45 to $8.85 per share, primarily due to anticipated acquisition-related charges and financing costs.
See More
Multiple Companies Report Earnings Beats, Significant Stock Movements
- Akamai Stock Surge: Akamai Technologies shares surged 25% after announcing a $1.8 billion seven-year contract with a leading U.S. frontier model provider, indicating strong demand for its Cloud Infrastructure Services and likely boosting future revenues significantly.
- Gen Digital's Positive Guidance: Gen Digital's stock rose 8% following its current-quarter and full-year revenue guidance that exceeded analysts' expectations, suggesting robust performance in the software market that could drive future stock price increases.
- Trade Desk Stock Plummet: Trade Desk's shares plummeted 14% as its current-quarter revenue guidance fell short of analyst expectations, highlighting intensified competition in the advertising technology sector that may impact the company's future market share.
- Gilead's Adjusted Outlook: Gilead Sciences shares dropped 3% after projecting a full-year adjusted loss of $1.05 to $0.65 per share, reflecting increased research and development and financing costs, which could negatively affect investor confidence.
See More
Gilead Reports Higher-Than-Expected Q1 Profit and Raises 2026 Sales Outlook
- Sales Outlook Raised: Gilead increased its 2026 sales forecast for the HIV prevention drug Yeztugo from $800 million to $1 billion, with Q1 sales reaching $166 million, surpassing Wall Street's $143 million estimate, indicating strong market demand and growth potential.
- Overall Sales Projection Upgraded: The company raised its overall 2026 sales outlook by $400 million to a range of $30 billion to $30.4 billion, reflecting confidence in future product lines despite facing financial costs related to acquisitions.
- Earnings Forecast Adjustment: Gilead now expects an adjusted loss for the year of $1.05 to $0.65 per share, down from a previous profit estimate of $8.45 to $8.85 per share, primarily due to costs associated with acquiring Arcellx and others, highlighting short-term financial pressure from its acquisition strategy.
- Strong Quarterly Performance: In Q1, Gilead reported adjusted earnings per share of $2.03, exceeding analyst expectations of $1.91, with revenue rising 4% to $6.96 billion, demonstrating robust growth across all business areas, as noted by the CEO's emphasis on demand-driven growth.
See More
Akamai Technologies Shares Surge 27% on $1.8 Billion Commitment
- Akamai Stock Surge: Shares of Akamai Technologies soared 27% after a leading U.S. frontier model provider committed to a $1.8 billion investment over seven years for its Cloud Infrastructure Services, enhancing market confidence and potentially driving future revenue growth.
- CoreWeave Revenue Guidance Miss: CoreWeave's second-quarter revenue guidance of $2.45 billion to $2.6 billion, with a midpoint of $2.53 billion, fell short of Wall Street's $2.69 billion expectation, resulting in a 7% stock decline, reflecting market concerns about its growth outlook.
- Microchip Earnings Beat: Microchip Technology's stock rose 3% following a fiscal fourth-quarter report that exceeded earnings and revenue expectations, with projected first-quarter revenue between $1.44 billion and nearly $1.47 billion, indicating strong performance in the semiconductor sector.
- Upwork Restructuring Plan: Upwork's announcement of a 24% workforce reduction to maintain profitability led to a 23% drop in its stock price, despite slightly lower-than-expected first-quarter earnings and revenue, showcasing the company's strategic response to evolving market conditions.
See More
Gilead Sciences Q1 2026 Earnings Call Highlights
- Significant Sales Growth: Gilead Sciences reported total product sales of $6.8 billion in Q1, an 8% year-over-year increase, with HIV sales reaching $5 billion, reflecting a robust 10% growth that underscores its strong market position and share gains in the HIV sector.
- Yeztugo Guidance Raised: Management has increased the 2026 Yeztugo sales guidance to approximately $1 billion, indicating confidence in product acceptance, while also projecting an 8% year-over-year growth in HIV sales, surpassing the previous guidance of 6%.
- Strong Financial Performance: The company reported a non-GAAP diluted EPS of $2.03, beating expectations by $0.12, with a product gross margin of 87% and an operating margin of 47%, showcasing its strengths in cost control and profitability.
- Positive Future Outlook: Management highlighted upcoming regulatory catalysts, including the priority review of BIC/LEN, which is expected to drive future revenue growth, while also noting a potential 2% growth headwind from policy changes that requires cautious navigation.
See More
Gilead Sciences Updates 2026 EPS Guidance to Loss Amid Q1 Beat
- EPS Guidance Cut: Gilead Sciences has drastically revised its 2026 non-GAAP EPS guidance from a profit of $8.45-$8.85 to a loss of $1.05-$1.65, primarily due to $11.5 billion in IPR&D charges and financing costs, which has negatively impacted market confidence.
- Sales Forecast Increased: Despite the EPS downgrade, Gilead projects full-year product sales of $30 billion to $30.4 billion, up from a prior estimate of $29.6 billion to $30 billion, indicating ongoing growth potential in its HIV and oncology treatment sectors.
- Significant HIV Growth: In Q1, Gilead's HIV franchise saw approximately a 10% year-over-year sales increase to around $5 billion, with Biktarvy alone generating about $3.4 billion, further solidifying its leadership in the antiviral market.
- Cash Flow Decline: As of March 31, 2026, Gilead's cash, cash equivalents, and marketable securities totaled $8.6 billion, down from $10.6 billion on December 31, 2025, reflecting financial pressure from acquisitions and R&D investments.
See More
Gilead Raises 2026 Sales Guidance Amid Acquisition Strategy
- Sales Guidance Increase: Gilead raised its 2026 product sales guidance to $30.0–$30.4 billion from $29.6–$30.0 billion, reflecting confidence in future growth despite pressures from acquisition-related costs.
- Aggressive Acquisition Strategy: The company is actively pursuing acquisitions, having announced deals for Arcellx, Ouro Medicines, and Tubulis since the start of 2026, aiming to bolster its oncology and inflammation pipeline while maintaining resilience in its HIV franchise.
- Strong Earnings Report: Gilead reported first-quarter revenues of $7.0 billion, a 4% year-over-year increase, with product sales rising 5% to $6.9 billion and HIV product sales growing 10% to $5.0 billion, demonstrating the strength of its core business.
- Earnings Outlook Cut: Despite the sales guidance increase, Gilead slashed its 2026 adjusted loss guidance to a range of $1.05 to $0.65 per share, down from previous earnings estimates of $8.45 to $8.85 per share, primarily due to anticipated acquisition-related charges and financing costs.
See More
Multiple Companies Report Earnings Beats, Significant Stock Movements
- Akamai Stock Surge: Akamai Technologies shares surged 25% after announcing a $1.8 billion seven-year contract with a leading U.S. frontier model provider, indicating strong demand for its Cloud Infrastructure Services and likely boosting future revenues significantly.
- Gen Digital's Positive Guidance: Gen Digital's stock rose 8% following its current-quarter and full-year revenue guidance that exceeded analysts' expectations, suggesting robust performance in the software market that could drive future stock price increases.
- Trade Desk Stock Plummet: Trade Desk's shares plummeted 14% as its current-quarter revenue guidance fell short of analyst expectations, highlighting intensified competition in the advertising technology sector that may impact the company's future market share.
- Gilead's Adjusted Outlook: Gilead Sciences shares dropped 3% after projecting a full-year adjusted loss of $1.05 to $0.65 per share, reflecting increased research and development and financing costs, which could negatively affect investor confidence.
See More
Gilead Reports Higher-Than-Expected Q1 Profit and Raises 2026 Sales Outlook
- Sales Outlook Raised: Gilead increased its 2026 sales forecast for the HIV prevention drug Yeztugo from $800 million to $1 billion, with Q1 sales reaching $166 million, surpassing Wall Street's $143 million estimate, indicating strong market demand and growth potential.
- Overall Sales Projection Upgraded: The company raised its overall 2026 sales outlook by $400 million to a range of $30 billion to $30.4 billion, reflecting confidence in future product lines despite facing financial costs related to acquisitions.
- Earnings Forecast Adjustment: Gilead now expects an adjusted loss for the year of $1.05 to $0.65 per share, down from a previous profit estimate of $8.45 to $8.85 per share, primarily due to costs associated with acquiring Arcellx and others, highlighting short-term financial pressure from its acquisition strategy.
- Strong Quarterly Performance: In Q1, Gilead reported adjusted earnings per share of $2.03, exceeding analyst expectations of $1.91, with revenue rising 4% to $6.96 billion, demonstrating robust growth across all business areas, as noted by the CEO's emphasis on demand-driven growth.
See More
